NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on the development of new treatment options for patients with gastrointestinal and endocrine disorders and medical needs. The Company’s clinical programs involve two therapeutic proteins: GATTEX (teduglutide) and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection). GATTEX is its analog of GLP-2, a protein involved in the regeneration and repair of the intestinal lining, and is in Phase 3 clinical development for parenteral dependent (PN) short bowel syndrome (SBS). NPSP558 is its recombinant human parathyroid hormone (PTH 1-84) that is in Phase 3 clinical development for hypoparathyroidism, a condition in which the body does not maintain normal calcium levels in the blood due to insufficient levels of parathyroid hormone. The Company’s subsidiaries include Allelix Biopharmaceuticals Inc., NPS Allelix Corp. (Allelix), Cinacalcet Royalty Sub LLC.